2010
A phase 2 trial of dasatinib in advanced melanoma
Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2010, 117: 2202-2208. PMID: 21523734, PMCID: PMC3116034, DOI: 10.1002/cncr.25766.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-kit mutationsPhase 2 trialResponse ratePartial responseMedian progression-free survivalMelanoma cell proliferationDaily dasatinibMucosal primaryPFS ratesStarting dosageCommon toxicitiesUnresectable melanomaAdvanced melanomaPleural effusionMelanoma patientsPredictive biomarkersMinor responseCombination trialsTumor assessmentDose reductionPatientsPrespecified endpointsDasatinibMelanoma
2009
A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies
Li J, Kluger H, Saif M, Murren J, Lee J, Kelly W, Rink L, Devine L, Sznol M. A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. Journal Of Clinical Oncology 2009, 27: 3554-3554. DOI: 10.1200/jco.2009.27.15_suppl.3554.Peer-Reviewed Original ResearchEarly discontinuationDose reductionDose levelsOral small-molecule inhibitorReceptor tyrosine kinasesAdvanced refractory malignanciesApparent PK interactionsHand-foot syndromeOral mTOR inhibitorDose/scheduleSoft tissue sarcomasDose of sirolimusMultiple receptor tyrosine kinasesAnti-tumor activityTumor cell proliferationDose cohortsECOG PSSunitinib doseInterstitial pneumonitisProgressive diseaseDose escalationTargeted agentsRefractory malignanciesTissue sarcomasPK interactionsA phase II trial of dasatinib in advanced melanoma
Kluger H, Dudek A, McCann C, Rink L, Ritacco J, Adrada C, Phouyaphone N, Southard N, Sznol M. A phase II trial of dasatinib in advanced melanoma. Journal Of Clinical Oncology 2009, 27: 9010-9010. DOI: 10.1200/jco.2009.27.15_suppl.9010.Peer-Reviewed Original ResearchStarting dosePartial responseC-kitNon-cytotoxic therapiesPhase 2 trialPhase II trialSubset of patientsMelanoma cell proliferationCommon toxicitiesDaily dasatinibMucosal primaryPo bidPrior chemotherapyII trialClinical responseUnresectable melanomaAdvanced melanomaMedian agePleural effusionMinor responseGrade IITumor assessmentDose reductionPreclinical evaluationPatients